.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Baxter
Daiichi Sankyo
Argus Health
US Department of Justice
Deloitte
Moodys
Chubb
Harvard Business School
McKesson

Generated: September 23, 2017

DrugPatentWatch Database Preview

Arformoterol tartrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for arformoterol tartrate and what is the scope of arformoterol tartrate freedom to operate?

Arformoterol tartrate
is the generic ingredient in one branded drug marketed by Sunovion and is included in one NDA. There are twelve patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Arformoterol tartrate has forty-six patent family members in thirteen countries.

There are three drug master file entries for arformoterol tartrate. One supplier is listed for this compound.

Summary for Generic Name: arformoterol tartrate

Tradenames:1
Patents:12
Applicants:1
NDAs:1
Drug Master File Entries: see list3
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list148
Patent Applications: see list5,237
Therapeutic Class:Respiratory Tract Agents
Drug Prices:see low prices
DailyMed Link:arformoterol tartrate at DailyMed

Pharmacology for Ingredient: arformoterol tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: arformoterol tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: arformoterol tartrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,342,132Formoterol tartrate process and polymorph► Subscribe
7,964,753Formoterol tartrate process and polymorph► Subscribe
8,114,912Bronchodilating .beta.-agonist compositions and methods► Subscribe
7,732,641Formoterol tartrate process and polymorph► Subscribe
9,730,890Bronchodilating beta-agonist compositions and methods► Subscribe
7,479,572Formoterol tartrate process and polymorph► Subscribe
6,268,533 Formoterol process► Subscribe
8,623,922Bronchodilating Beta-agonist compositions and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: arformoterol tartrate

Country Document Number Estimated Expiration
Spain2178015► Subscribe
World Intellectual Property Organization (WIPO)02083079► Subscribe
Austria259779► Subscribe
World Intellectual Property Organization (WIPO)9821175► Subscribe
Denmark1446380► Subscribe
Portugal1082293► Subscribe
Spain2554476► Subscribe
European Patent Office1381346► Subscribe
European Patent Office0938467► Subscribe
European Patent Office2165999► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Mallinckrodt
US Department of Justice
Medtronic
Baxter
Harvard Business School
US Army
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot